Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Haematologica|September 8, 2018
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A Eyre, Harriet S Walter, Sunil Iyengar, et al.
Rheumatology (Oxford, England)|March 14, 2024
Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseasesAmy Fuller, Jennie Hancox, Hywel C Williams, et al.
Rheumatology Advances in Practice|June 15, 2022
Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink AurumGeorgina Nakafero, Matthew J Grainge, Tim Card, et al.
Leukemia & Lymphoma|April 4, 2019
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphomaMarc Sorigue, Mark Bishton, Eva Domingo-Domenech, et al.
Therapeutic Advances in Hematology|June 5, 2023
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemiaWojciech Jurczak, Nagah Elmusharaf, Christopher P Fox, et al.
British Journal of Haematology|April 20, 2021
Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology GuidelineNimish Shah, Toby A Eyre, David Tucker, et al.
Leukemia & Lymphoma|April 23, 2015
High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow TransplantationChristopher P Fox, Ariane Boumendil, Norbert Schmitz, et al.
Blood|October 10, 2015
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation eventDavid M Burns, Rose Tierney, Claire Shannon-Lowe, et al.
Eclinicalmedicine|September 25, 2023
Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluationGeorgina Nakafero, Tim Card, Matthew J Grainge, et al.
BMJ (Clinical Research Ed.)|May 30, 2023
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UKGeorgina Nakafero, Matthew J Grainge, Hywel C Williams, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Haematologica|September 8, 2018
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A Eyre, Harriet S Walter, Sunil Iyengar, et al.
Rheumatology (Oxford, England)|March 14, 2024
Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseasesAmy Fuller, Jennie Hancox, Hywel C Williams, et al.
Rheumatology Advances in Practice|June 15, 2022
Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink AurumGeorgina Nakafero, Matthew J Grainge, Tim Card, et al.
Leukemia & Lymphoma|April 4, 2019
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphomaMarc Sorigue, Mark Bishton, Eva Domingo-Domenech, et al.
Therapeutic Advances in Hematology|June 5, 2023
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemiaWojciech Jurczak, Nagah Elmusharaf, Christopher P Fox, et al.
British Journal of Haematology|April 20, 2021
Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology GuidelineNimish Shah, Toby A Eyre, David Tucker, et al.
Leukemia & Lymphoma|April 23, 2015
High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow TransplantationChristopher P Fox, Ariane Boumendil, Norbert Schmitz, et al.
Blood|October 10, 2015
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation eventDavid M Burns, Rose Tierney, Claire Shannon-Lowe, et al.
Eclinicalmedicine|September 25, 2023
Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluationGeorgina Nakafero, Tim Card, Matthew J Grainge, et al.
BMJ (Clinical Research Ed.)|May 30, 2023
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UKGeorgina Nakafero, Matthew J Grainge, Hywel C Williams, et al.
Pageof 13